Market closed
Context Therapeutics/$CNTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Context Therapeutics
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Ticker
$CNTX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
12
ISIN
US21077P1084
Website
CNTX Metrics
BasicAdvanced
$64M
-
-$0.35
2.12
-
Price and volume
Market cap
$64M
Beta
2.12
52-week high
$1.04
52-week low
$0.55
Average daily volume
122K
Financial strength
Current ratio
48.802
Quick ratio
47.024
Long term debt to equity
0.091
Total debt to equity
0.213
Management effectiveness
Return on assets (TTM)
-38.01%
Return on equity (TTM)
-55.59%
Valuation
Price to book
0.7
Price to tangible book (TTM)
0.7
Price to free cash flow (TTM)
-1.855
Growth
Earnings per share change (TTM)
-73.55%
3-year earnings per share growth (CAGR)
-43.22%
CNTX News
AllArticlesVideos
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 week ago
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
GlobeNewsWire·2 weeks ago
Context Therapeutics Announces Chief Medical Officer Transition
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Context Therapeutics stock?
Context Therapeutics (CNTX) has a market cap of $64M as of May 19, 2025.
What is the P/E ratio for Context Therapeutics stock?
The price to earnings (P/E) ratio for Context Therapeutics (CNTX) stock is 0 as of May 19, 2025.
Does Context Therapeutics stock pay dividends?
No, Context Therapeutics (CNTX) stock does not pay dividends to its shareholders as of May 19, 2025.
When is the next Context Therapeutics dividend payment date?
Context Therapeutics (CNTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Context Therapeutics?
Context Therapeutics (CNTX) has a beta rating of 2.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.